[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Toxoplasmosis Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 40 pages | ID: T86A44F9264FEN
VPAResearch

US$ 1,699.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Toxoplasmosis Drug pipeline report- 2020 is an annual R&D review of Toxoplasmosis pipeline candidates. The report presents the current status of all major Toxoplasmosis therapeutic compounds. Detailed insights into Toxoplasmosis pipeline development, current status, companies, drug profiles and Toxoplasmosis preclinical and clinical trials are included.

2020 Toxoplasmosis Pipeline Market Insights
Toxoplasmosis disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Toxoplasmosis therapies, pipeline by phase and others are included.

Toxoplasmosis pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Toxoplasmosis Therapeutic Drug candidates
Both active and inactive Toxoplasmosis pipeline drug candidates are included in the report

Toxoplasmosis Clinical Trials and preclinical Studies
Toxoplasmosis In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Toxoplasmosis pipeline market developments
Toxoplasmosis Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Toxoplasmosis pipeline companies in active development
The report analyzes Toxoplasmosis pipeline of the below companies-

GlaxoSmithKline Plc, Motif Bio Plc, Vaxinano SE, Vyera Pharmaceuticals LLC

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
4 Companies investing in Toxoplasmosis pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Toxoplasmosis pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included
1. TOXOPLASMOSIS PIPELINE MARKET INSIGHTS, 2020

1.1 Toxoplasmosis Disease Overview
1.2 Toxoplasmosis Drug Pipeline Snapshot, 2020
  1.2.1 Toxoplasmosis Pipeline Drugs by Phase
  1.2.2 Toxoplasmosis Pipeline Drugs by Company
  1.2.3 Toxoplasmosis Pipeline Drugs by Mechanism of Action
  1.2.4 Toxoplasmosis Pipeline Drugs by Route of Administration

2. TOXOPLASMOSIS COMPANY WISE PIPELINE DETAILS

GlaxoSmithKline Plc Toxoplasmosis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Motif Bio Plc Toxoplasmosis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Vaxinano SE Toxoplasmosis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Vyera Pharmaceuticals LLC Toxoplasmosis Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. TOXOPLASMOSIS DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. TOXOPLASMOSIS PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts


More Publications